Switch theme
Sign up to access all valuation multiples
Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production.
2007
n/a
LTM Revenue $374M
LTM EBITDA $60.9M
$2.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sinocelltech Group has a last 12-month revenue (LTM) of $374M and a last 12-month EBITDA of $60.9M.
In the most recent fiscal year, Sinocelltech Group achieved revenue of $349M and an EBITDA of $51.8M.
Sinocelltech Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sinocelltech Group valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $374M | XXX | $349M | XXX | XXX | XXX |
| Gross Profit | $358M | XXX | $334M | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 96% | XXX | XXX | XXX |
| EBITDA | $60.9M | XXX | $51.8M | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| EBIT | $88.0M | XXX | $94.2M | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $22.8M | XXX | $15.5M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 4% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $229M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sinocelltech Group's stock price is CNY 40 (or $5).
Sinocelltech Group has current market cap of CNY 17.6B (or $2.4B), and EV of CNY 20.1B (or $2.8B).
See Sinocelltech Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.8B | $2.4B | XXX | XXX | XXX | XXX | $0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sinocelltech Group has market cap of $2.4B and EV of $2.8B.
Sinocelltech Group's trades at 8.0x EV/Revenue multiple, and 53.8x EV/EBITDA.
Equity research analysts estimate Sinocelltech Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sinocelltech Group has a P/E ratio of 107.5x.
See valuation multiples for Sinocelltech Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.4B | XXX | $2.4B | XXX | XXX | XXX |
| EV (current) | $2.8B | XXX | $2.8B | XXX | XXX | XXX |
| EV/Revenue | 7.5x | XXX | 8.0x | XXX | XXX | XXX |
| EV/EBITDA | 45.7x | XXX | 53.8x | XXX | XXX | XXX |
| EV/EBIT | 31.6x | XXX | 29.5x | XXX | XXX | XXX |
| EV/Gross Profit | 7.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 107.5x | XXX | 157.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -80.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSinocelltech Group's last 12 month revenue growth is 14%
Sinocelltech Group's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Sinocelltech Group's rule of 40 is 5% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sinocelltech Group's rule of X is 50% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sinocelltech Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Growth | 33% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 5% | XXX | 29% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 50% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 36% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 69% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sinocelltech Group acquired XXX companies to date.
Last acquisition by Sinocelltech Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Sinocelltech Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sinocelltech Group founded? | Sinocelltech Group was founded in 2007. |
| Where is Sinocelltech Group headquartered? | Sinocelltech Group is headquartered in China. |
| Is Sinocelltech Group publicy listed? | Yes, Sinocelltech Group is a public company listed on SHG. |
| What is the stock symbol of Sinocelltech Group? | Sinocelltech Group trades under 688520 ticker. |
| When did Sinocelltech Group go public? | Sinocelltech Group went public in 2020. |
| Who are competitors of Sinocelltech Group? | Similar companies to Sinocelltech Group include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Sinocelltech Group? | Sinocelltech Group's current market cap is $2.4B |
| What is the current revenue of Sinocelltech Group? | Sinocelltech Group's last 12 months revenue is $374M. |
| What is the current revenue growth of Sinocelltech Group? | Sinocelltech Group revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Sinocelltech Group? | Current revenue multiple of Sinocelltech Group is 7.5x. |
| Is Sinocelltech Group profitable? | Yes, Sinocelltech Group is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sinocelltech Group? | Sinocelltech Group's last 12 months EBITDA is $60.9M. |
| What is Sinocelltech Group's EBITDA margin? | Sinocelltech Group's last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Sinocelltech Group? | Current EBITDA multiple of Sinocelltech Group is 45.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
